Mondaq USA: Litigation, Mediation & Arbitration > Sovereign Immunity: Public Sector Government
Holland & Knight
It's an old aphorism that "you can't fight City Hall."
Morrison & Foerster LLP
As a general rule, when a contractor signs a full settlement and release with respect to a dispute with the Government, the dispute is considered settled, and the Government is released...
Holland & Knight
It's an old aphorism that "you can't fight City Hall." Now it's time to add a related aphorism: "you can't sue the government under the federal Defend Trade Secrets Act (DTSA)...
Davis & Gilbert
Although there's been much talk of an epic battle between states and the federal government that will determine the scope of federal preemption in the student loan space,
Orrick
Imagine this: After years of acrimonious litigation, your company has finally defeated a meritless False Claims Act (FCA) lawsuit.
Carlton Fields
The Foreign Sovereign Immunities Act, 28 U.S.C. §1602 et seq. (FSIA), is silent on the issue of criminal immunity for foreign sovereigns.
Mintz
In an unusual decision in an unusual case—a dispute between sovereigns—a U.S. appellate court recently vacated a domestic arbitration award on grounds other than those provided in Section 10...
RPX Corporation
The third quarter of 2018 saw the resolution of some lingering uncertainties from Q2, as judicial rulings and proposed reforms set the stage for additional changes to the patent ecosystem in the months ahead.
Carlton Fields
Florida Appeals Court Decisions: Week of September 24 - 28, 2018
Osha Liang LLP
The U.S. Court of Appeals for the Federal Circuit ("Federal Circuit") affirmed the Patent Trial & Appeal Board's (PTAB's) ...
McDermott Will & Emery
The US Court of Appeals for the Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) finding that tribal immunity does not apply to inter partes review (IPR) proceedings.
Morrison & Foerster LLP
This month, we highlight significant developments from July 2018, including the FDA's Biosimilar Action Plan for "reducing gaming of FDA requirements or other attempts to unfairly delay competition" ...
Kramer Levin Naftalis & Frankel LLP
In a previous post here, we described constitutional and procedural challenges to inter partes review ("IPR") in the Oil States and SAS Institute cases taken up by the U.S. Supreme Court.
Akin Gump Strauss Hauer & Feld LLP
On July 20, 2018, the Federal Circuit affirmed in Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals, Inc. that tribal immunity cannot be asserted in IPRs.
Marshall, Gerstein & Borun LLP
The Federal Circuit recently affirmed the PTAB's decision that tribal immunity cannot be asserted in an IPR (Saint Regis Mohawk Tribe v. Mylan Pharma Inc., Case No. 2018-1638 (Fed. Cir. July 20, 2018).
Dickinson Wright PLLC
On Friday, July 20, 2018, the Court of Appeals for the Federal Circuit addressed the controversial application of sovereign immunity for inter partes review in Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc.
Oblon, McClelland, Maier & Neustadt, L.L.P
The Federal Circuit issued its decision in Saint Regis Mohawk Tribe et al v. Mylan Pharmaceuticals Inc., et al (18-1638) on July 20, 2018.
Foley Hoag LLP
In Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc.
Seyfarth Shaw LLP
Indian tribes ability to shield patents from review at the United States Patent and Trademark Office's ("USPTO") Patent Trial and Appeal Board ("PTAB") took another blow at the Federal Circuit.
Jones Day
This ruling may have eliminated the practice of transferring patents to Native American tribes for immunization from IPR proceedings.
Most Popular Recent Articles
RPX Corporation
The third quarter of 2018 saw the resolution of some lingering uncertainties from Q2, as judicial rulings and proposed reforms set the stage for additional changes to the patent ecosystem in the months ahead.
Carlton Fields
Florida Appeals Court Decisions: Week of September 24 - 28, 2018
Carlton Fields
The Foreign Sovereign Immunities Act, 28 U.S.C. §1602 et seq. (FSIA), is silent on the issue of criminal immunity for foreign sovereigns.
Osha Liang LLP
The U.S. Court of Appeals for the Federal Circuit ("Federal Circuit") affirmed the Patent Trial & Appeal Board's (PTAB's) ...
Mintz
In an unusual decision in an unusual case—a dispute between sovereigns—a U.S. appellate court recently vacated a domestic arbitration award on grounds other than those provided in Section 10...
Kramer Levin Naftalis & Frankel LLP
In a previous post here, we described constitutional and procedural challenges to inter partes review ("IPR") in the Oil States and SAS Institute cases taken up by the U.S. Supreme Court.
Dickinson Wright PLLC
On Friday, July 20, 2018, the Court of Appeals for the Federal Circuit addressed the controversial application of sovereign immunity for inter partes review in Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc.
Jones Day
In a case of first impression, the PTAB recently decided that the doctrine of tribal sovereign immunity does not apply to inter partes review proceedings.
Morrison & Foerster LLP
This month, we highlight significant developments from July 2018, including the FDA's Biosimilar Action Plan for "reducing gaming of FDA requirements or other attempts to unfairly delay competition" ...
Marshall, Gerstein & Borun LLP
The Federal Circuit recently affirmed the PTAB's decision that tribal immunity cannot be asserted in an IPR (Saint Regis Mohawk Tribe v. Mylan Pharma Inc., Case No. 2018-1638 (Fed. Cir. July 20, 2018).
Article Search Using Filters
Related Topics
Mondaq Advice Center (MACs)
Popular Authors
Popular Contributors
Up-coming Events Search
Tools
Font Size:
Translation
Channels
Mondaq on Twitter
Partners
In association with